FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384700534> ?p ?o ?g. }

• W4384700534 endingPage "100681" @default.
• W4384700534 startingPage "100681" @default.
• W4384700534 abstract "Thrombosis associated with thrombocytopenia was a matter of concern post first and second doses of BNT162b2 and ChAdOx1 COVID-19 vaccines. Therefore, it is important to investigate the risk of thrombocytopenic, thromboembolic and haemorrhagic events following a second dose of BNT162b2 and ChAdOx1 COVID-19 vaccines. We conducted a large-scale self-controlled case series analysis, using routine primary care data linked to hospital data, among 12.3 million individuals (16 years old and above) in England. We used the nationally representative Oxford-Royal College of General Practitioners (RCGP) sentinel network database with baseline and risk periods between 8th December 2020 and 11th June 2022. We included individuals who received two vaccine (primary) doses of the BNT162b2 mRNA (Pfizer-BioNTech) and two vaccine doses of ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines in our analyses. We carried out a self-controlled case series (SCCS) analysis for each outcome using a conditional Poisson regression model with an offset for the length of risk period. We reported the incidence rate ratios (IRRs) and 95% confidence intervals (CI) of thrombocytopenic, thromboembolic (including arterial and venous events) and haemorrhagic events, in the period of 0–27 days after receiving a second dose of BNT162b2 or ChAdOx1 vaccines compared to the baseline period (14 or more days prior to first dose, 28 or more days after the second dose and the time between 28 or more days after the first and 14 or more days prior to the second dose). We adjusted for a range of potential confounders, including age, sex, comorbidities and deprivation. Between December 8, 2020 and February 11, 2022, 6,306,306 individuals were vaccinated with two doses of BNT162b2 and 6,046,785 individuals were vaccinated with two doses of ChAdOx1. Compared to the baseline, our analysis show no increased risk of venous thromboembolic events (VTE) for both BNT162b2 (IRR 0.71, 95% CI: 0.65–0.770) and ChAdOx1 (IRR 0.91, 95% CI: 0.84–0.98); and similarly there was no increased risk for cerebral venous sinus thrombosis (CVST) for both BNT162b2 (IRR 0.87, 95% CI: 0.41–1.85) and ChAdOx1 (IRR 1.73, 95% CI: 0.82–3.68). We additionally report no difference in IRR for pulmonary embolus, and deep vein thrombosis, thrombocytopenia, including idiopathic thrombocytopenic purpura (ITP), and haemorrhagic events post second dose for both BNT162b2. Reassuringly, we found no associations between increased risk of thrombocytopenic, thromboembolic and haemorrhagic events post vaccination with second dose for either of these vaccines. Data and Connectivity: COVID-19 Vaccines Pharmacovigilance study." @default.
• W4384700534 created "2023-07-20" @default.
• W4384700534 creator A5004448818 @default.
• W4384700534 creator A5008167189 @default.
• W4384700534 creator A5011009600 @default.
• W4384700534 creator A5014846731 @default.
• W4384700534 creator A5029278184 @default.
• W4384700534 creator A5047427172 @default.
• W4384700534 creator A5049433267 @default.
• W4384700534 creator A5052532012 @default.
• W4384700534 creator A5053448161 @default.
• W4384700534 creator A5065866497 @default.
• W4384700534 creator A5069835701 @default.
• W4384700534 creator A5088297765 @default.
• W4384700534 creator A5088724040 @default.
• W4384700534 creator A5089614039 @default.
• W4384700534 creator A5089948156 @default.
• W4384700534 creator A5091026819 @default.
• W4384700534 date "2023-09-01" @default.
• W4384700534 modified "2023-10-16" @default.
• W4384700534 title "Thrombocytopenic, thromboembolic and haemorrhagic events following second dose with BNT162b2 and ChAdOx1: self-controlled case series analysis of the English national sentinel cohort" @default.
• W4384700534 cites W1486552319 @default.
• W4384700534 cites W3094542430 @default.
• W4384700534 cites W3160138987 @default.
• W4384700534 cites W3160661056 @default.
• W4384700534 cites W3166101893 @default.
• W4384700534 cites W3184226105 @default.
• W4384700534 cites W3186359837 @default.
• W4384700534 cites W3187516448 @default.
• W4384700534 cites W3193768668 @default.
• W4384700534 cites W3202237317 @default.
• W4384700534 cites W3209286501 @default.
• W4384700534 cites W3215567024 @default.
• W4384700534 cites W4200153348 @default.
• W4384700534 cites W4200220307 @default.
• W4384700534 cites W4200368736 @default.
• W4384700534 cites W4205505191 @default.
• W4384700534 cites W4212851080 @default.
• W4384700534 cites W4213441356 @default.
• W4384700534 cites W4213455358 @default.
• W4384700534 cites W4214616932 @default.
• W4384700534 cites W4223427029 @default.
• W4384700534 cites W4281710539 @default.
• W4384700534 cites W4283820581 @default.
• W4384700534 cites W4285086230 @default.
• W4384700534 cites W4291582766 @default.
• W4384700534 cites W4298139814 @default.
• W4384700534 cites W4307640332 @default.
• W4384700534 cites W4309765959 @default.
• W4384700534 cites W4310060182 @default.
• W4384700534 cites W4312182367 @default.
• W4384700534 doi "https://doi.org/10.1016/j.lanepe.2023.100681" @default.
• W4384700534 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37671127" @default.
• W4384700534 hasPublicationYear "2023" @default.
• W4384700534 type Work @default.
• W4384700534 citedByCount "0" @default.
• W4384700534 crossrefType "journal-article" @default.
• W4384700534 hasAuthorship W4384700534A5004448818 @default.
• W4384700534 hasAuthorship W4384700534A5008167189 @default.
• W4384700534 hasAuthorship W4384700534A5011009600 @default.
• W4384700534 hasAuthorship W4384700534A5014846731 @default.
• W4384700534 hasAuthorship W4384700534A5029278184 @default.
• W4384700534 hasAuthorship W4384700534A5047427172 @default.
• W4384700534 hasAuthorship W4384700534A5049433267 @default.
• W4384700534 hasAuthorship W4384700534A5052532012 @default.
• W4384700534 hasAuthorship W4384700534A5053448161 @default.
• W4384700534 hasAuthorship W4384700534A5065866497 @default.
• W4384700534 hasAuthorship W4384700534A5069835701 @default.
• W4384700534 hasAuthorship W4384700534A5088297765 @default.
• W4384700534 hasAuthorship W4384700534A5088724040 @default.
• W4384700534 hasAuthorship W4384700534A5089614039 @default.
• W4384700534 hasAuthorship W4384700534A5089948156 @default.
• W4384700534 hasAuthorship W4384700534A5091026819 @default.
• W4384700534 hasBestOaLocation W43847005341 @default.
• W4384700534 hasConcept C120665830 @default.
• W4384700534 hasConcept C121332964 @default.
• W4384700534 hasConcept C126322002 @default.
• W4384700534 hasConcept C187212893 @default.
• W4384700534 hasConcept C194828623 @default.
• W4384700534 hasConcept C2908647359 @default.
• W4384700534 hasConcept C44249647 @default.
• W4384700534 hasConcept C61511704 @default.
• W4384700534 hasConcept C71924100 @default.
• W4384700534 hasConcept C72563966 @default.
• W4384700534 hasConcept C73269764 @default.
• W4384700534 hasConcept C77350462 @default.
• W4384700534 hasConcept C99454951 @default.
• W4384700534 hasConceptScore W4384700534C120665830 @default.
• W4384700534 hasConceptScore W4384700534C121332964 @default.
• W4384700534 hasConceptScore W4384700534C126322002 @default.
• W4384700534 hasConceptScore W4384700534C187212893 @default.
• W4384700534 hasConceptScore W4384700534C194828623 @default.
• W4384700534 hasConceptScore W4384700534C2908647359 @default.
• W4384700534 hasConceptScore W4384700534C44249647 @default.
• W4384700534 hasConceptScore W4384700534C61511704 @default.
• W4384700534 hasConceptScore W4384700534C71924100 @default.
• W4384700534 hasConceptScore W4384700534C72563966 @default.
• W4384700534 hasConceptScore W4384700534C73269764 @default.

• next